Merck & Co. (MRK) PT Set at $56.00 by Jefferies Group

Jefferies Group set a $56.00 target price on Merck & Co. (NYSE:MRK) in a research report released on Friday morning. The brokerage currently has a hold rating on the stock. Jefferies Group also issued estimates for Merck & Co.’s Q1 2018 earnings at $0.99 EPS, FY2018 earnings at $4.14 EPS, FY2020 earnings at $4.51 EPS and FY2022 earnings at $5.01 EPS.

A number of other research analysts have also commented on the company. Barclays raised Merck & Co. from an equal weight rating to an overweight rating and upped their price objective for the company from $62.00 to $64.00 in a report on Thursday, April 5th. SunTrust Banks raised Merck & Co. from a hold rating to a buy rating and upped their price objective for the company from $54.00 to $72.00 in a report on Tuesday, January 16th. ValuEngine raised Merck & Co. from a hold rating to a buy rating in a report on Wednesday, January 10th. BMO Capital Markets upped their price objective on Merck & Co. from $68.00 to $72.00 and gave the company an outperform rating in a report on Wednesday, January 17th. Finally, DZ Bank raised Merck & Co. from a hold rating to a buy rating in a report on Tuesday, February 13th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the stock. The company has a consensus rating of Buy and an average target price of $66.53.

How to Become a New Pot Stock Millionaire

Shares of NYSE MRK opened at $58.65 on Friday. The company has a current ratio of 1.33, a quick ratio of 1.06 and a debt-to-equity ratio of 0.62. Merck & Co. has a one year low of $52.83 and a one year high of $66.41. The firm has a market capitalization of $154,141.17, a price-to-earnings ratio of 14.74, a PEG ratio of 2.41 and a beta of 0.77.

Merck & Co. (NYSE:MRK) last issued its quarterly earnings data on Friday, February 2nd. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.94 by $0.04. Merck & Co. had a return on equity of 28.61% and a net margin of 6.40%. The firm had revenue of $10.43 billion for the quarter, compared to analyst estimates of $10.48 billion. During the same period in the prior year, the firm posted $0.89 EPS. The company’s revenue for the quarter was up 3.1% on a year-over-year basis. equities analysts forecast that Merck & Co. will post 4.16 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, April 6th. Stockholders of record on Thursday, March 15th were given a dividend of $0.48 per share. The ex-dividend date was Wednesday, March 14th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 3.27%. Merck & Co.’s payout ratio is 48.24%.

In other news, Director Wendell P. Weeks sold 5,000 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $53.57, for a total transaction of $267,850.00. Following the completion of the sale, the director now directly owns 5,100 shares in the company, valued at approximately $273,207. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.32% of the company’s stock.

Several hedge funds have recently made changes to their positions in MRK. Santori & Peters Inc. bought a new stake in shares of Merck & Co. during the 4th quarter worth $110,000. NewSquare Capital LLC raised its position in Merck & Co. by 728.3% in the third quarter. NewSquare Capital LLC now owns 14,801 shares of the company’s stock valued at $115,000 after purchasing an additional 13,014 shares during the last quarter. Stevens First Principles Investment Advisors raised its position in Merck & Co. by 79.3% in the fourth quarter. Stevens First Principles Investment Advisors now owns 2,080 shares of the company’s stock valued at $117,000 after purchasing an additional 920 shares during the last quarter. Avestar Capital LLC bought a new position in Merck & Co. in the fourth quarter valued at about $130,000. Finally, Balentine LLC raised its position in Merck & Co. by 1.0% in the second quarter. Balentine LLC now owns 2,107 shares of the company’s stock valued at $135,000 after purchasing an additional 20 shares during the last quarter. Institutional investors and hedge funds own 74.60% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Merck & Co. (MRK) PT Set at $56.00 by Jefferies Group” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.chaffeybreeze.com/2018/04/17/merck-co-mrk-pt-set-at-56-00-by-jefferies-group.html.

About Merck & Co.

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Analyst Recommendations for Merck & Co. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply